Nearly four-fifths of Teleflex’s $127.8 million revenue increase came from one acquisition. The VI Business generated $99.0 million of the additional sales in the three months ended June 30, 2026, pushing revenue to $570.3 million from $442.5 million a year earlier.
That is the easy part of the filing. The harder part is what happened underneath: operating income fell to $72.8 million from $91.1 million, and operating margin dropped 7.8 percentage points to 12.8%. Teleflex added sales faster than it added operating profit, which is not the usual order of events.
Management points to three pressures in particular: tariffs enacted in 2025, VI’s lower gross-margin profile, and amortization tied to the acquisition. Gross margin slipped to 58.2% from 60.1%, even as gross profit rose to $331.7 million.
Teleflex lays out that bridge in the 10-Q:
"Gross margin for the three months ended June 30, 2026 decreased 190 basis points, or 3.2%, compared to the prior year period, primarily due to the adverse impact from tariffs enacted in 2025, the lower gross margin profile of the VI Business and amortization of intangible assets related to the VI Business."
Teleflex, Form 10-Q, Aug. 6, 2026
The acquisition therefore did two things at once. It enlarged the revenue base, but it also brought a different margin profile and a new set of amortization charges into the comparison. Research and development rose 70.3% to $45.1 million, adding another cost line as the combined business absorbs the deal.
The balance sheet offers a snapshot, though it comes with its own footnotes. Cash rose 18.3% to $300.2 million, while inventory fell 49.3% to $351.9 million and accounts receivable declined 29.0% to $364.6 million. Teleflex said the $147.9 million cash-flow improvement primarily reflected lower tax payments, reduced inventory outflows as it moderated inventory levels, and proceeds from a litigation settlement. Cash is up, but not all of the increase came from ordinary operating profit.
Debt also entered the deal arithmetic. Interest expense rose to $28.0 million from $21.7 million, and Teleflex said borrowings used to fund the VI acquisition were the primary reason. The company reported $2.2B of net debt at the latest annual snapshot, while also disclosing $250.0 million of common-stock repurchases during the six months ended June 30.
The six-month numbers make the pattern harder to dismiss as a single three-month stretch. Revenue rose 30.6%, helped by $198.1 million from VI, while gross margin fell 3.7 percentage points. Teleflex also cited quality-remediation costs and excess and obsolete inventory charges in the six-month margin decline, suggesting the margin pressure reflects more than one tariff line.
Its stock closed at $136.94 on Aug. 5, down 2.2% for the day, after a 33.8% gain over six months. The market context is narrow but relevant: Teleflex is carrying a $6.1B market capitalization against an $8.3B enterprise value, so the filing leaves investors weighing a larger sales engine against lower current operating conversion.
Teleflex’s next report will provide the next comparable read on how much revenue the VI Business contributes and where the consolidated gross and operating margins land. For now, the filing’s central trade-off is simple: more top line, less operating line. Medical-device arithmetic can be fussy.
Teleflex’s 10-Q attributes the margin decline to tariffs, VI’s lower-margin profile, acquisition-related amortization, and additional remediation costs.